MAP2K7 and melanoma: Since his melanoma had a B-raf mutation, present in approximately 50% of melanomas, he was then given oral targeted therapy with dabrafenib 150 mg orally twice daily, which inhibited B-raf signaling, and trametinib 2 mg daily, which inhibited MEK signaling, as was reviewed by Robert et al. [3].